- Home
- VTGN vs CTMX Comparison
VTGN vs CTMX Comparison
Compare VTGN & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- CTMX
- Stock Information
- Founded
- VTGN 1998
- CTMX 2008
- Country
- VTGN United States
- CTMX United States
- Employees
- VTGN N/A
- CTMX N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- VTGN Health Care
- CTMX Health Care
- Exchange
- VTGN Nasdaq
- CTMX Nasdaq
- Market Cap
- VTGN 62.9M
- CTMX 60.7M
- IPO Year
- VTGN N/A
- CTMX 2015
- Fundamental
- Price
- VTGN $2.26
- CTMX $2.38
- Analyst Decision
- VTGN
- CTMX Buy
- Analyst Count
- VTGN 0
- CTMX 2
- Target Price
- VTGN N/A
- CTMX $2.50
- AVG Volume (30 Days)
- VTGN 96.9K
- CTMX 9.5M
- Earning Date
- VTGN 06-10-2025
- CTMX 05-12-2025
- Dividend Yield
- VTGN N/A
- CTMX N/A
- EPS Growth
- VTGN N/A
- CTMX 128.27
- EPS
- VTGN N/A
- CTMX 0.49
- Revenue
- VTGN $698,000.00
- CTMX $147,557,000.00
- Revenue This Year
- VTGN N/A
- CTMX N/A
- Revenue Next Year
- VTGN N/A
- CTMX N/A
- P/E Ratio
- VTGN N/A
- CTMX $4.90
- Revenue Growth
- VTGN N/A
- CTMX 23.81
- 52 Week Low
- VTGN $1.90
- CTMX $0.40
- 52 Week High
- VTGN $4.75
- CTMX $2.81
- Technical
- Relative Strength Index (RSI)
- VTGN 47.92
- CTMX 83.13
- Support Level
- VTGN $2.25
- CTMX $0.91
- Resistance Level
- VTGN $2.38
- CTMX $2.55
- Average True Range (ATR)
- VTGN 0.12
- CTMX 0.21
- MACD
- VTGN 0.02
- CTMX 0.18
- Stochastic Oscillator
- VTGN 45.71
- CTMX 91.17
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.